Project Grant R41AG091877
Award Date 9/20/25
Completion Date 9/19/26
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- The National Institute on Aging awarded a $4.6 million Project Grant to Cornell University under the Aging Research program (CFDA 93.866) to develop new imaging techniques for measuring microvascular blood flow in Alzheimer's disease and related dementia models. The award will support the design of an adaptive excitation source for 2-photon and 3-photon fluorescence microscopy to simultaneously measure blood flow speeds in approximately 300 cortical or 50 deep white matter microvessels. This...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Translucence Biosystems, Inc. a $1,025,651 Project Grant to develop and qualify a Vasculature Subtraction Parenchymal Quantification (VSPQ) workflow. The VSPQ workflow aims to enhance Translucence Biosystems' proprietary 3D brain imaging and analysis platform to precisely measure the distribution of antibody-based therapeutics within the brain parenchyma, addressing a key technological...
- This Project Grant award of $437,875 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund a 2-year research project at the University of California, San Diego to quantify neurovascular protein lifetimes in the central nervous system under healthy, aging, and Alzheimer's disease conditions. The key objectives are to generate a comprehensive atlas of neurovascular protein lifetimes and identify changes associated with aging and Alzheimer's disease. The project will...
- This federal Project Grant award of $495,731.00, awarded on September 20, 2025 by the National Institute on Aging (CFDA 93.866 Aging Research program), supports the evaluation of Viewmind's ability to detect beta-amyloid and tau burden consistent with Alzheimer's disease in persons with mild cognitive impairment (MCI) using machine learning, virtual reality, and eye-tracking technology. The project aims to develop a non-invasive, cost-effective, and rapid diagnostic tool that can accurately...
- This Project Grant award from the National Science Foundation (CFDA 47.041 - Engineering) provides $597,232.00 to the University of Illinois to develop a new imaging technique called "intrinsic signal optoretinography" for detecting early functional biomarkers of Alzheimer's disease in the retina. The research aims to establish this noninvasive, quantitative method for measuring changes in the retina that could indicate neurodegeneration in the brain before structural damage is...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Tauvision, Inc. provides $493,384 to develop an eyedrop-based, non-invasive diagnostic test for Alzheimer's disease. The project aims to optimize a fluorescent compound that can label pathological protein aggregates in the eye and be imaged using standard ophthalmology equipment, allowing for a direct measurement of central nervous system biomarkers. In Phase 1, the researchers will improve the...
- This $481,250 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to Vanderbilt University Medical Center (VUMC) on September 1, 2024. The award supports the development of an innovative, non-invasive MRI imaging technique to assess membrane lipid properties in Alzheimer's disease (AD). The key objectives are to: 1) verify the relationship between the MRI nuclear Overhauser enhancement (NOE) signal and lipid properties using reconstituted phospholipid...
- The National Institute on Aging (NIA), under the Federal Aging Research program (CFDA 93.866), awarded a $245,148 project grant to Eyenexo LLC to develop an automated rodent behavior testing system for non-invasively assessing early-stage Alzheimer's disease (AD). The project aims to develop a behavior biomarker that can differentiate AD from normal aging by studying defensive behaviors triggered by looming stimuli, which are linked to early AD pathology in the midbrain region. The 2-year...
- This federal Project Grant award, valued at $1,552,000.00 and provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports a research study examining the relationship between markers of vascular and immune dysfunction, such as platelet aggregation and neutrophil levels, and their association with dementia risk and increased Alzheimer's disease (AD) biomarkers. The study, conducted by New York University School of Medicine, aims to integrate biofluid biomarker data with...
- This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...